Belizatinib

Cat. No.: HY-17603

CAS No.: 1357920-84-3

Molecular Formula: $C_{33}H_{44}FN_5O_3$

Molecular Weight: 577.73

Target: ALK; Trk Receptor

Pathway: Protein Tyrosine Kinase/RTK; Neuronal Signaling

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 300 mg/mL (519.27 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.7309 mL	8.6546 mL	17.3091 mL
5 mM	0.3462 mL	1.7309 mL	3.4618 mL
10 mM	0.1731 mL	0.8655 mL	1.7309 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC_{50} of 0.7 nM for wild-type recombinant ALK kinase.

IC_{50} & Target

IC50: 0.7 nM (ALK)[1]

In Vitro

TSR-011 has antitumour activity in the clinical trials.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Pharm Biomed Anal. 2019 Apr 6;171:132-147.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Sullivan I, et al. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol. 2016 Jan;8(1):32-47.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA